Clinical trial NCT05600088: Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With (N)STEMI or Unstable Angina
Official title: Clinical Investigation of Intracoronary Cryotherapy Using the CryoTherapy System (CTS) for High-risk Plaque in Patients With (Non-)ST-segment Elevation Myocardial Infarction (NSTEMI) or Unstable Angina
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Coronary Artery Disease
Coronary Syndrome
Cryotherapy Effect
Myocardial Infarction
Myocardial Disease
Atherosclerosis, Coronary
Lead sponsor: Cryotherapeutics SA
Sponsor class: INDUSTRY
Collaborators: name: CoreAalst BV
First posted: 2022-10-31
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: up to 10 subjects with NSTEMI or unstable angina undergoing cryotherapy treatment of coronary vulnerable plaque lesions. Once This safety cohort has been enrolled, additional 20 subjects will be enrolled to further confirm feasibility and safety of the device.
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The POLARSTAR study is an early safety and feasibility study to evaluate the performance and safety of the CryoTherapy System (CTS) for the treatment of coronary plaque lesions that are not obstructing blood flow but are at high-risk of rupture which would cause a major heart attack. The CTS is used to apply local freezing of the lesion using a balloon catheter, controlled by a console that regulates in- and outflow of a cooling agent into the catheter. The treatment is expected to stabilize the lesion, diminishing the risk of rupture. The study will enrol subjects with acute coronary disease who have suitable coronary lesions. Subjects will be followed for 1 year after the CTS treatment. Baseline identification of lesions will be done using Coronary CT-angiography (CCTA), which will be repeated at 3 and 9 months after procedure.

Detailed description: The POLARSTAR study is an early feasibility study to evaluate the safety and performance of the CryoTherapy System (CTS) medical device, consisting of a console and a balloon catheter. The CTS is designed to deliver local cryo-energy to vulnerable plaque lesions in the coronary arteries, aiming to stabilize the plaque to reduce the risk of rupture and subsequent cardiac events. The study will enrol up to 10 subjects with NSTEMI or unstable angina, who underwent successful Percutaneous Coronary Intervention (PCI) of their culprit coronary lesion, and who were identified to have presence of at least 1 non-culprit suitable plaque lesion at high-risk of rupture. After providing informed consent the subjects will undergo a Coronary CT-angiography (CCTA) to confirm suitability of the coronary plaque lesion. A single high-risk plaque lesion will be treated by the investigators, with Intra-vascular Ultrasound (IVUS) imaging prior to and after CTS treatment. Subjects will be followed clinically for up to one year after the CTS treatment, and will have follow-up CCTA assessments at 3 and 9 months post-procedure. Primary endpoint will be Major cardiac events rate at 3 months post procedure.

Eligibility criteria: Inclusion Criteria:

1. Subject is at least 18 years old.
2. Subject has acute cardiac pain/angina consistent with acute coronary syndrome eligible for coronary angiography meeting one of the following criteria:

   1. (Non-)ST-segment elevation myocardial infarction ((N)STEMI) with rise/fall of cardiac enzymes (troponin I or T) with at least one value above the 99th percentile of the upper reference limit requiring PCI within 72 hours from diagnosis
   2. Unstable angina
3. Successful PCI (defined as diameter stenosis less than 30% and TIMI 3 flow on final angiography without procedural complication) of the culprit lesion.
4. Subject has at least one high-risk plaque meeting the criteria below:

   1. Located in a non-culprit vessel,
   2. High-risk plaque lesion on CCTA and at least one of the following features:

      1. Presence of low-attenuation plaque (HU\<50) and/or
      2. Positive remodelling (remodelling index \>1.1) and/or
      3. Napkin ring sign and/or
      4. Plaque burden ≥70%
   3. Lesion length ≤ 20 mm.
   4. Diameter stenosis on invasive angiography between 30% and 70% on coronary angiogram or negative physiology assessment (FFR\>0.80 or non-hyperemic pressure ratios (NHPR) \>0.89).
   5. Reference vessel diameter (RVD) \< 3.75 mm and \> 2.00 mm in diameter
   6. Investigator considers that lesions are accessible.
   7. If more than two suitable lesions available, investigator will select the most appropriate lesion for cryotherapy treatment.
5. Subject is able to provide consent and has signed and dated the informed consent form.

Exclusion Criteria:

1. Subject is hemodynamically unstable (cardiogenic shock, hypotension needing inotropes, hypoxia needing intubation, refractory ventricular arrhythmias, and IABP).
2. Subject has ongoing ST-segment elevation myocardial infarction.
3. Subject had a procedural complication during the Acute coronary syndrome (ACS) PCI procedure.
4. Subject has history of Coronary Artery Bypass Graft (CABG) or planned CABG within 12 months after the index procedure.
5. Subject has known reduced Left Ventricular Ejection Fraction \< 30%.
6. Subject has known severe valvular heart disease.
7. Subject has known severe renal insufficiency (eGFR \<30 ml/min/1.72 m2).
8. Subject has any life-threatening conditions or medical comorbidity resulting in life expectancy \< 12 months.
9. Subject is currently participating in another clinical investigation that has not yet reached its primary endpoint.
10. Subject is pregnant or lactating, or NOT surgically sterile (tubal ligation or hysterectomy) or NOT postmenopausal for at least 6 months or is a female with childbearing potential without effective contraception (pill, patch, ring, diaphragm, implant and intrauterine device).

Angiographic exclusion criteria:

1. Visible distal embolization/no-reflow following culprit lesions PCI.
2. Left main coronary artery disease (visual diameter stenosis \> 50%).
3. Stent thrombosis/restenosis as a culprit lesion.
4. CTS lesion involving a bifurcation (defined as lesions involving side branches \>2.0 mm).
5. Angiographic or CCTA evidence of severe calcification and/or marked tortuosity of the index vessel and/or lesion.
6. Thrombotic lesions
7. Ostial lesions

Primary outcomes:
measure: Safety: Rate of Cryotherapy related adverse events
timeFrame: 90 days post-procedure
Secondary outcomes:
measure: Safety: Rate of Cryotherapy related events
timeFrame: 1 year post-procedure
measure: Device success
timeFrame: end of CTS treatment
measure: CTS procedure success
timeFrame: end of CTS treatment
measure: Imaging: CCTA assessed Minimum lumen area (MLA)
timeFrame: 90 days post-procedure
measure: Imaging: CCTA assessed Minimum lumen area (MLA)
timeFrame: 9 months post-procedure
measure: Imaging: CCTA assessed area stenosis
timeFrame: 3 months post-procedure
measure: Imaging: CCTA assessed area stenosis
timeFrame: 9 months post-procedure
measure: Imaging: CCTA assessed lesion plaque burden
timeFrame: 3 months post-procedure
measure: Imaging: CCTA assessed lesion plaque burden
timeFrame: 9 months post-procedure
measure: Imaging: CCTA assessed Total plaque volume
timeFrame: 3 months post-procedure
measure: Imaging: CCTA assessed Total plaque volume
timeFrame: 9 months post-procedure
Other outcomes:
Locations:
city: Tbilisi
country: Georgia
facility: Israeli-Georgian Research Clinic Helsicore
city: Tbilisi
country: Georgia
facility: Tbilisi Heart Center
city: Kaunas
country: Lithuania
facility: Hospital of Lithuanian University of health sciences Kauno Klinikos
city: Klaipèda
country: Lithuania
facility: Klaipèda University Hospital
city: Vilnius
country: Lithuania
facility: Vilnius University Hospital Santaros Klinikos
Study officials:
affiliation: Israeli_Georgian research Clinic Helsicore, Tbilisi, Georgia
name: Irakli Gogorishvili, MD
role: PRINCIPAL_INVESTIGATOR
References: